SITC

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Retrieved on: 
Thursday, November 9, 2023
Annual general meeting, Food, IND, Insurance, CLDN6, Research, Immunotherapy, New Drug Application, Conference, Trial of the century, SITC, Toxicity, Context, Society, CD3, Cryptocurrency, Pharmaceutical industry, Vaccine

PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent and upcoming business highlights.

Key Points: 
  • Cash and cash equivalents of $21.7 million as of September 30, 2023
    PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent and upcoming business highlights.
  • Research and development (“R&D”) expenses were $4.5 million for the third quarter 2023, as compared to $2.1 million for the same period in 2022.
  • General and administrative expenses were $1.7 million for the third quarter 2023, as compared to $2.0 million for the same period in 2022.
  • Context reported a net loss of $5.9 million for the third quarter 2023, as compared to $3.9 million for the same period in 2022.

Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 9, 2023
PD-L1, Research, A11, Ono Pharmaceutical, A24, Disease, WT1, Clinical trial, Epitope, Patient, Autoimmune disease, Allele, Pembrolizumab, Neoplasm, DCR, ORR, Ovarian cancer, SITC, Stomach, Cancer, Society, Vaccine, Pharmaceutical industry, Cryptocurrency

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, provided a business and financial update for the third quarter of 2023.

Key Points: 
  • BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, provided a business and financial update for the third quarter of 2023.
  • Presented positive data from ongoing Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting (SITC 2023) held November 1-5.
  • Completed enrollment of 20 patients for the ongoing Phase 1b study of CUE-101 in combination with pembrolizumab.
  • The Company reported collaboration revenue of approximately $3.7 million and $1.1 million for the nine months ended September 30, 2023 and 2022, respectively.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Renal cell carcinoma, Trae Elston, Anticipation, Liver disease, Research, Annual general meeting, Safety, Research and development, Therapy, Completeness, Colorectal cancer, Hypertelorism, CRC, Liver, PD, FC, ESMO, Administration, Patient, MSS, Tumor microenvironment, Immunotherapy, G&A, RCC, DCR, TME, Melanoma, Cancer, SITC, Roche, R, Oncology, Phase II, Neoplasm, Society, Cell, Pharming, Biopsy, Medical imaging, Pharmaceutical industry, Vaccine, Cryptocurrency

WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Xilio anticipates activating clinical trial sites for the Phase 1 combination dose escalation in the fourth quarter of 2023.
  • As previously announced, Xilio anticipates reporting preliminary safety data from the Phase 1 clinical trial into the third dose level in the fourth quarter of 2023.
  • General & Administrative (G&A) Expenses: G&A expenses were $6.3 million for the quarter ended September 30, 2023, compared to $7.2 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $16.7 million for the quarter ended September 30, 2023, compared to $19.8 million for the quarter ended September 30, 2022.

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, November 9, 2023
Granzyme, Natural history, Antigen, Safety, Annual general meeting, DNA, Therapy, Risk, Peptide, Clinical trial, Mouse, Insurance, Patient, Research and development, Immunotherapy, PDAC, G&A, Lymph, Lymphatic system, RFS, Conference, BRAF, Cancer, Development, Pancreatic cancer, Death, SITC, V600E, Phase II, Neoplasm, AMP, OS, Society, AACR, Pharmaceutical industry, Vaccine, Amphiphile, Research, Elicio Berriz

R&D Expense: R&D expense for the third quarter of 2023 was $7.3 million, compared to $4.6 million for the third quarter of 2022.

Key Points: 
  • R&D Expense: R&D expense for the third quarter of 2023 was $7.3 million, compared to $4.6 million for the third quarter of 2022.
  • G&A Expense: G&A expense for the third quarter of 2023 was $3.5 million, compared to $1.2 million for the third quarter of 2022.
  • Net Loss and Net Loss per Share: Net loss for the third quarter of 2023 was $10.7 million, compared to $7.2 million for the third quarter of 2022.
  • Net loss per share for the third quarter of 2023 was $1.27 compared to $22.67 for the third quarter of 2022.

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Tumor-associated macrophage, Research, Annual general meeting, Renal cell carcinoma, Hereditary diffuse gastric cancer, Head, Colorectal cancer, ESMO, Administration, Patient, Triple-negative breast cancer, ASCO, MSK, FDA, Lung cancer, G&A, Immunotherapy, Patent, ORR, Ovarian cancer, MPH, Cancer, Trial of the century, Diagnosis, Nivolumab, SITC, Operation, Antibody, Research and development, R, Congress, Orphan, Society, TNBC, ISAC, NSCLC, Pharmaceutical industry, Vaccine, Cryptocurrency

Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.

Key Points: 
  • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.
  • Research and Development (R&D) Expenses – R&D expenses were $15.0 million for the quarter ended September 30, 2023, compared to $19.0 million for the same quarter in 2022.
  • General and Administrative (G&A) Expenses – G&A expenses were $5.8 million for the quarter ended September 30, 2023, compared to $5.5 million for the same quarter in 2022.
  • Loss from Operations – Loss from operations was $18.2 million for the quarter ended September 30, 2023, compared to $22.3 million for the same quarter in 2022.

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Johns Hopkins University, Deltex Medical Group, Annual general meeting, Pakistan Society of Neuro-Oncology, Progression-free survival, University, HSCT, ASH, Cohort, Glioblastoma, TTP, IND, GBM, Leukemia, Patient, Research and development, Abstract, Cleveland Clinic, PFS, Research, Immunotherapy, CRS, IPSC, ORR, CD33, Ovarian cancer, Cancer, Development, CML, Survival, Bone marrow, SITC, Arms, AML, Gamma delta T cell, Society, SNO, CD123, Poster, KOL, University of Chicago, DRI, Pharmaceutical industry, Medical imaging

Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.

Key Points: 
  • Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30, 2023.
  • The presentation at ASH will highlight clinical data updating the efficacy results of INB-100 including complete responses (CRs) and durability.
  • Cash: As of September 30, 2023, the Company had cash of $12.9 million, compared to $17.0 million as of June 30, 2023.

Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors

Retrieved on: 
Monday, December 18, 2023
Research, Technology, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Renal cell carcinoma, Safety, Annual general meeting, Immunoglobulin G, Karen Teff, Clinical trial, Patient, Regulatory T cell, Kidney, Artificial intelligence, Immunotherapy, Interleukin, Neoplasm, RCC, CD25, Therapy, Melanoma, SITC, Eosinophil, Skin, Cell, NK, Pharmaceutical industry, Vaccine

AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors.

Key Points: 
  • AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors.
  • This is encouraging as the anti-tumor activity has been observed in heavily pre-treated patients whose tumors had progressed through checkpoint inhibitors.
  • Clinical data from the Phase 1/2 study were presented at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in November.
  • Created by Biolojic Design, AU-007 is the first computationally designed monoclonal antibody to be tested in a clinical trial.

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Health, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, Research, Safety, NYSE, Annual general meeting, Therapy, Northwest Biotherapeutics, Supernova, Patient, Immunotherapy, Neoplasm, NYSE American, Partnership, SITC, Growth, Society, Poster, Pharmaceutical industry, Cryptocurrency

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights.
  • The poster also detailed the clinical readiness of the product and plans to launch a Phase 1 study in 2024.
  • The company also announced the appointment of Alan Stewart, previously a Calidi advisor, to the Board of Directors.
  • In conjunction with the transaction closing, Calidi entered into a forward purchase agreement with a consortium of funds for up to $10 million.

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, Uveal melanoma, MDSC, Webcast, Sale, Interest, Liver disease, Pressure, Policy, ICI, Cancer, Commercial Operating System, Liver, Investment, Patient, PFS, Tumor microenvironment, Marketing, FACS, Neoplasm, TME, MD, SITC, Growth, Immunotherapy, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • “Today marks an important milestone for TriSalus as we host our first quarterly earnings call as a public company.
  • The seven percent improvement in the third quarter of 2023 is due to increased factory volumes and improved operations efficiency.
  • Operating losses are $18.5 million and $40.0 million, respectively, for the third quarter and nine months ended September 30, 2023.

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Downregulation and upregulation, ISCB Senior Scientist Award, Annual general meeting, Safety, ALT, Cohort, UPCR, AIH, Immunosuppression, Clinical trial, Patient, KZR, OLE, Week, American College of Rheumatology, Immunotherapy, Mount Everest, G&A, Pharmacokinetics, Polymyositis, American College, PD-1, University, Dermatomyositis, Lupus nephritis, SITC, Total, Autoimmune hepatitis, Growth, CRR, Congress, ACR, APLAR, Society, Sec61, Pharmaceutical industry, Rheumatology, Kezar Pavilion

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
  • In addition, Kezar recently announced a strategic restructuring to prioritize long-term growth and focus resources on its clinical-stage programs.
  • Actions to prioritize clinical programs and implement cost saving measures are expected to extend Kezar’s cash runway into late 2026.
  • Research and development expenses for the third quarter of 2023 increased by $9.8 million to $23.7 million compared to $13.9 million in the third quarter of 2022.